Alejandro Martı́n

8.7k total citations
128 papers, 2.8k citations indexed

About

Alejandro Martı́n is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Alejandro Martı́n has authored 128 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Pathology and Forensic Medicine, 54 papers in Oncology and 35 papers in Genetics. Recurrent topics in Alejandro Martı́n's work include Lymphoma Diagnosis and Treatment (71 papers), Chronic Lymphocytic Leukemia Research (31 papers) and Viral-associated cancers and disorders (18 papers). Alejandro Martı́n is often cited by papers focused on Lymphoma Diagnosis and Treatment (71 papers), Chronic Lymphocytic Leukemia Research (31 papers) and Viral-associated cancers and disorders (18 papers). Alejandro Martı́n collaborates with scholars based in Spain, France and United States. Alejandro Martı́n's co-authors include Jesús F. San Miguel, María‐Victoria Mateos, Alberto Órfão, Ramón García‐Sánz, María‐Belén Vídriales, Jean‐Philippe Spano, D. Khayat, Marı́a Dolores Caballero, C López-Berges and Gema Mateo and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Alejandro Martı́n

115 papers receiving 2.8k citations

Peers

Countries citing papers authored by Alejandro Martı́n

Since Specialization

Citations

This map shows the geographic impact of Alejandro Martı́n's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alejandro Martı́n with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alejandro Martı́n more than expected).

Fields of papers citing papers by Alejandro Martı́n

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alejandro Martı́n. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alejandro Martı́n. The network helps show where Alejandro Martı́n may publish in the future.

Co-authorship network of co-authors of Alejandro Martı́n

This figure shows the co-authorship network connecting the top 25 collaborators of Alejandro Martı́n. A scholar is included among the top collaborators of Alejandro Martı́n based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alejandro Martı́n. Alejandro Martı́n is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Chimeric antigen receptor T‐cell therapy outcomes in T cell/histiocyte‐rich large B‐cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study 2025 ·HemaSphere ·Mariana Bastos‐Oreiro, Gloria Iacoboni, Vı́ctor Navarro, A Caballero, (unknown), (unknown), Aitana Balaguer‐Roselló, Mi Kwon, Sonia González de Villambrosía, Rafael Hernani, Ana Jiménez Ubieto, Rebeca Bailén, (unknown), Alejandro Martı́n, Pere Barba	1
2	Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group 2024 ·Clinical Cancer Research ·(unknown), Carlos Grande, (unknown), (unknown), Antonio Gutiérrez, Ángel Ramírez Páyer, Eva Giné, (unknown), María José Terol, (unknown), Rafael Andreu, (unknown), Adolfo de la Fuente, María C. Viguria, María Jesús Peñarrubia, Ana Jiménez Ubieto, Santiago Montes‐Moreno, Armando López‐Guillermo, (unknown), Alejandro Martı́n	0
3	Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma 2024 ·Blood Advances ·Thomas E. Witzig, Lubomir Sokol, (unknown), (unknown), Alejandro Martı́n, Ranjana H. Advani, (unknown), (unknown), Ana Marín‐Niebla, Antonia Rodríguez Izquierdo, María José Terol, Eva Domingo‐Doménech, (unknown), Nawal Bendris, (unknown), Mollie Leoni, Francine M. Foss	7
4	Peripheral T‐cell lymphoma with a T follicular‐helper phenotype: A different entity? Results of the Spanish Real‐T study 2023 ·British Journal of Haematology ·Alejandro Martı́n, Socorro Marıá Rodríguez-Pinilla, Eva Domingo‐Doménech, Fina Climent, Joaquín Sánchez‐García, Javier López Jiménez, (unknown), Josep Castellví, (unknown), Sonia González de Villambrosía, José Codina, Belén Navarro, Guillermo Rodríguez‐Domínguez, Juan José Borrero Martín, Máximo Fraga, (unknown), (unknown), Raúl Córdoba	3
5	Lenalidomide in combination with R‐ESHAP in patients with relapsed or refractory diffuse large B‐cell lymphoma: A phase 2 study from GELTAMO 2023 ·British Journal of Haematology ·Alejandro Martı́n, Mónica Baile, Guillermo Rodríguez‐Domínguez, Iván Dlouhy, Juan‐Manuel Sancho, Isidro Jarque, Eva González‐Barca, Antonio Salar, (unknown), Carlos Grande, Juan Bergua, Santiago Montes‐Moreno, Alba Redondo, Anna Enjuanes, Elı́as Campo, Armando López‐Guillermo, Dolores Caballero	0
6	Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options 2023 ·Journal of Clinical Medicine ·Alejandro Martı́n, (unknown), Norma C. Gutiérrez	8
7	Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial 2021 ·Bone Marrow Transplantation ·Ruth Pettengell, (unknown), Ariane Boumendil, Roderick J. Johnson, Bernd Metzner, Alejandro Martı́n, Joanna Romejko‐Jarosińska, Isabelle Bence‐Bruckler, (unknown), Carsten Utoft Niemann, Stephen Robinson, Eva Kimby, Norbert Schmitz, Peter Dreger, A. H. Goldstone, Silvia Montoto	7
8	Real-World Evidence of Brexucabtagene Autoleucel for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma 2021 ·Blood ·Gloria Iacoboni, Kai Rejeski, (unknown), Annalisa Chiappella, (unknown), Lucía López‐Corral, Mariana Bastos‐Oreiro, (unknown), Christian Schmidt, Cecilia Carpio, Juan Luís Reguera, Mi Kwon, Alejandro Martı́n, Pier Luigi Zinzani, Paolo Corradini, Marion Subklewe, Pere Barba	7
9	Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP 2021 ·Blood Advances ·Sophie Bernard, Hervé Ghesquières, Olivier Casasnovas, (unknown), María Gomes da Silva, Pierre Feugier, Franck Morschhauser, (unknown), Loïc Renaud, Richard Greil, Alejandro Martı́n, Sebastian Grosicki, Koen Van Eygen, Christiane Copie‐Bergman, Corinne Haïoun, Catherine Thiéblemont	7
10	Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial 2019 ·Cancer Medicine ·Francisco‐Javier Peñalver, (unknown), (unknown), Pilar Giraldo, Alejandro Martı́n, Carlos Montalbán, Juan‐Manuel Sancho, (unknown), María José Terol, F. Capote, Antonio Gutiérrez, (unknown), Andrés López, Antonio Salar, Gil Rodríguez‐Caravaca, Miguel Canales, (unknown), (unknown)	4
11	Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A 2018 ·Leukemia Research ·Charikleia Kelaïdi, Thorsten Braun, (unknown), Alice Marceau‐Renaut, Grégory Lazarian, Juliette Soret, Sophie Cereja, Rémi Letestu, Virginie Éclache, (unknown), Fanny Baran‐Marszak, Lionel Adès, Claude Preudhomme, Alejandro Martı́n, Pierre Fenaux, Claude Gardin	3
12	Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome 2017 ·Hematological Oncology ·Marc Sorigué, Santiago Mercadal, Sara Alonso, Rubén Fernández-Álvarez, Olga García, (unknown), Helena Pomares, Miguel Alcoceba, (unknown), (unknown), Eva González‐Barca, Alejandro Martı́n, Anna Sureda, Dolores Caballero, Josep‐María Ribera, Juan‐Manuel Sancho	11
13	Post Relapse Survival Rates in Diffuse Large B-Cell Lymphoma 2016 ·Blood ·Andrew McMillan, Alejandro Martı́n, Corinne Haïoun, Annalisa Chiappella, Alice Di Rocco, Antonio Rueda, (unknown), Andrew Davies	5
14	Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma 2010 ·Haematologica ·Fanny Baran‐Marszak, (unknown), Stéphanie Harel, Christelle Laguillier, (unknown), Rémy Gressin, Alejandro Martı́n, Rémi Fagard, Nadine Varin‐Blank, Florence Ajchenbaum‐Cymbalista, Dominique Ledoux	49
15	Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation 2010 ·Annals of Oncology ·(unknown), Alejandro Martı́n, E. Condé, Antonio Pascual, Inmaculada Heras, Rosario Varela, Javier de la Rubia, (unknown), José L. Díez‐Martín, Carlos Panizo, (unknown), María Pascual, (unknown), Eva González‐Barca, Marı́a Dolores Caballero	9
16	Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project 2009 ·Haematologica ·Pilar Giraldo, Pilar Alfonso, (unknown), (unknown), Abelardo Bárez, Rafael Franco, David Alonso, Alejandro Martı́n, (unknown), Miguel Pocovı́	54
17	Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells 2009 ·British Journal of Haematology ·Ernesto Pérez Persona, Gema Mateo, Ramón García‐Sánz, María‐Victoria Mateos, Natalia de las Heras, Alfonso García de Coca, José M. Hernández, Josefina Galende, Guillermo Martín–Núñez, Abelardo Bárez, José María Alonso, Alejandro Martı́n, C López-Berges, Alberto Órfão, Jesús F. San Miguel, María‐Belén Vídriales	82
18	Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature 2004 ·Pathologie Biologie ·Jeanne Simon, Olivier Lortholary, Nadine Caillat‐Vigneron, Martine Raphaël, Alejandro Martı́n, J Brière, Stéphane Barète, Olivier Hermine, (unknown)	30
19	Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti‐tumour effect 2002 ·British Journal of Haematology ·Alejandro Martı́n, Ramón García‐Sánz, José‐Ángel Hernández‐Rivas, Joan Bladé, (unknown), Javier Fernández‐Calvo, Marcos González, Gema Mateo, Alberto Órfão, Jesús F. San Miguel	52
20	Completud de dos cálculos lógicos de Leibniz 2001 ·Communities in ADDI (University of the Basque Country) ·Alejandro Martı́n, Xavier Caicedo	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact